Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:
- Myocardial infarction, or heart attack, as well as congestive heart failure
Hypertension (high blood pressure), with increased risk of stroke
- Venous thromboembolism
- Thrombosis of vascular access
- Tumor progression or recurrence
If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Four Types of Professional Malpractice
When you hear the word “malpractice,” what’s the first image that comes to mind? A doctor perf…Read More 14 Dec 2018, Friday
Sacred Sites and Ski Resorts: The Hopi Tribe and Reclaimed Wastewater
What constitutes a “public nuisance”? And does an injury rooted in religious belief override gen…Read More 13 Dec 2018, Thursday
Field Test Fail: When Traffic Stops Go Wrong
Traffic stops on New Year’s Eve may be a good way of deterring drunk driving, but a pair of Georgi…Read More 12 Dec 2018, Wednesday